Are peptides legal now? Not in the way the headlines suggest. On 30 October 2026 HHS published a draft policy saying it will not take enforcement action against licensed 503A pharmacies and physicians that compound six peptides under strict conditions. The statute and the 503A bulks list are unchanged.
The argument of this piece is that the HHS peptide policy is a narrow, revocable promise of non-enforcement, not a change in what is legal. It covers BPC-157, TB-500, MOTS-c, Epitalon, KPV and Semax, but only one salt form of each, only the routes HHS lists, only from FDA-registered manufacturers and only on a patient-specific prescription. Everything outside those lines, including the research-use-only vials sold online and the larger 503B outsourcing facilities, sits exactly where it sat on 29 October. The decision that would actually change the law, an FDA rule on the 503A bulks list, has no published date. Read the policy as a gate left ajar for one kind of pharmacy, not as a gate taken down.
Nothing below is medical or legal advice, and this page does not tell anyone whether to use a peptide, which pharmacy to use or how a pharmacy should comply. It reports what the Federal Register notice says, with each document linked, and what published legal analyses say the policy's appendices contain. The HHS appendix PDF returned an access error when we tried to read it on 4 November 2026, so the routes and conditions below are attributed to the law firms that read it. For the status of each compound, see the Ozemback peptide tracker.
What is the HHS peptide enforcement discretion policy?
The HHS peptide policy is a draft document titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", announced in the Federal Register on 30 October 2026 as FR Doc. 2026-22192, docket HHS-OASH-2026-0496, and signed by Health Secretary Robert F. Kennedy Jr. The notice was filed on 28 October. Its operative sentence is that HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding a drug with a peptide bulk substance listed in Appendix A. The stated reason is "significant interest" in these peptides and "the lack of availability of approved products", and the policy runs only while the 503A bulks list is developed through rulemaking.
The notice is explicit about what the document is not. It "does not establish any rights for any person and is not binding on HHS or the public", and HHS says it may revisit the policy, in whole or in part, if a safety signal or product quality issue arises. Section 503A of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, still lets a pharmacy compound from a bulk substance only if that substance meets one of the statutory routes, such as a USP monograph, a component of an approved drug or a place on the 503A bulks list. None of the six peptides gained any of those on 30 October. What changed is the federal government's stated intention about enforcement, which is a policy choice that a later notice can reverse.
Which peptides does the HHS policy cover, and in what forms?
Appendix A names six peptides, the same six that FDA's Pharmacy Compounding Advisory Committee voted to support at its meeting of 23 and 24 July 2026, against the recommendation of FDA's own scientists, as our account of that meeting sets out. According to the readings of BakerHostetler and of the FDA Law Blog, both published on 28 October, each peptide is tied to one chemical form and a closed list of routes. The table reproduces those routes as reported. It says nothing about strength, schedule or use, because the policy does not set a dose and neither does Ozemback.
| Peptide | Form named in Appendix A | Routes allowed (as reported) | Ozemback file |
|---|---|---|---|
| BPC-157 | Acetate | Subcutaneous, intramuscular, oral, topical | BPC-157 |
| TB-500 | Acetate | Subcutaneous or intramuscular injection | TB-500 |
| MOTS-c | Acetate | Subcutaneous or intramuscular injection | MOTS-c |
| Epitalon | Acetate | Subcutaneous or intramuscular injection, dispensed in intermittent courses | Epitalon |
| KPV | Acetate | Topical and oral | KPV |
| Semax | Free base | Intranasal | Semax |
The table is narrower than it looks. A pharmacy compounding KPV as an injection, or Semax as anything other than a nasal product, falls outside the policy on the reported reading, and so does any peptide not on the list, including the GLP-1 class and popular names such as GHK-Cu that were not part of the July votes. Appendix B, according to the FDA Law Blog, also fixes the amino acid sequence, structure, molecular weight and molecular formula each bulk substance must match. A product that is the right peptide in the wrong salt, or the right salt by the wrong route, is not covered. That precision is the point: HHS chose to describe six specific products, not six names.
HHS did not legalise six peptides. It told six kinds of pharmacy work that nobody will knock on the door, for now, if every box is ticked.
What conditions do pharmacies have to meet under the HHS policy?
BakerHostetler counts ten conditions, and the FDA Law Blog lists the same substance in a slightly different order. The compounder must be a licensed pharmacist or physician. The bulk substance must come from a manufacturer registered with FDA under section 510 of the Act that follows current good manufacturing practice, with a certificate of analysis that names the plant's physical location and carries testing consistent with Appendix B; the FDA Law Blog calls that testing "more onerous than what compounders currently rely on". If the substance passes through a repacker or reseller, that firm must have validated the manufacturer and its certificate. The product needs a valid patient-specific prescription and may contain only one listed peptide, which rules out blends of two or more.
The remaining conditions are about traceability. Serious adverse events and product quality problems go to FDA through MedWatch and to the states where the product is made and sent, and the FDA Law Blog reads the text as also requiring reports on the products compounded. The label must say "This is a compounded drug product. Not for resale." The only device that may be packed with the product is an FDA-cleared syringe. Oral forms need documentation of adequate bioavailability, a standard Drug Topics notes the document does not define. Drug Topics also flags that it is unclear how the syringe rule fits an intranasal Semax product. Every other requirement of section 503A, including sanitary conditions, still applies.
Does the HHS policy make BPC-157 legal to buy or sell?
No, and the gap between the two ideas is where most readers will get hurt. The policy covers compounding by licensed pharmacies and physicians against a prescription. BakerHostetler states that it does not cover 503B outsourcing facilities, and NPR's report of 28 October says the same. It also does not cover products sold as research chemicals or as dietary supplements. A vial of BPC-157 labelled "for research use only" and sold online was outside federal law before 30 October and remains outside it now, for the reasons our explainer on selling research peptides covers. HHS itself frames the policy as a safer channel than those products, which is an admission that they still exist and are still not covered.
The second gap is the states. Pharmacies are licensed and inspected by state boards, and federal non-enforcement does not bind a state. Drug Topics warns that stakeholders "should not assume" state boards will take the same approach, and the FDA Law Blog calls state adoption "a big unknown". A state that treats compounding from a non-listed bulk substance as a violation of its own pharmacy law can still act. The third gap is time. Because the document is a draft and not binding, a pharmacy that builds a line of business on it is betting on the next notice, the next safety report and the next secretary. That is a legitimate commercial bet, but it is not the same thing as legality.
Why did HHS issue the policy, and what do critics say?
The strongest case for the policy is the one HHS makes in its own text. Demand for these peptides exists, no approved product does, and the alternative most people use is the research-use-only market the FDA Law Blog describes as "a thriving" gray market supplied largely from overseas. On that reading, a regulated pharmacy working from a registered manufacturer, a tested certificate and a prescription, with mandatory adverse-event reporting, is a clear improvement on an unlabelled vial bought online. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, told NPR the policy is a "more accountable alternative". The reporting requirement could also produce the first systematic safety data on these compounds in the United States.
The counterargument is about process and evidence. FDA's scientists recommended against lifting the restrictions in July, and the advisory committee's vote is a recommendation, not a finding of safety or efficacy. Robert Steinbrook of Public Citizen told NPR that Kennedy acted unilaterally and "undermined the FDA", and the Partnership for Safe Medicines has filed a citizen petition asking FDA to reject the committee's recommendation. The FDA Law Blog adds that the policy is framed entirely as an HHS document and does not state FDA's position. Our view is that both sides are partly right: the policy improves the supply chain for six products while leaving their evidence base exactly as thin as it was, and the second fact matters more to anyone deciding whether to use them.
What happens next with the HHS peptide policy and the 503A list?
Two clocks are running. The first is the comment period. The Federal Register notice allows written comments for two weeks after publication on 30 October 2026, through docket HHS-OASH-2026-0496 on regulations.gov, and the FDA Law Blog notes that HHS expects comments to "supply additional evidence" for the rulemaking. After that, HHS can finalise, revise or drop the draft. The second clock is the rule itself. The notice says "FDA's future rulemakings may propose adding some or all of these peptides" to the 503A bulks list, which is the step that would give them a statutory footing. Our explainer on the 503A bulks list shows how that list is built and why entries take so long.
History does not suggest speed. The FDA Law Blog authors write that, after 15 years, only six bulk substances have been moved from FDA's interim 503A list through notice-and-comment rulemaking, and that the final rule "could take quite a while". Until a rule is published, the HHS policy is the whole of the federal position, and it can change with a single notice. The Ozemback peptide tracker records the policy against each of the six compounds and will record the rulemaking when it appears. The honest answer to the question in the headline is therefore short: six peptides are now tolerated in one channel under ten conditions, and none of them is legal in the sense most people mean.
Sources
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, Federal Register Vol. 91 No. 209, pp. 68526-68527, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496, 30 October 2026. www.federalregister.gov
- BakerHostetler, HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 October 2026. www.bakerlaw.com
- Karla L. Palmer and Charles D. Snow, The PEPTIDE-L wave reaches HHS: enforcement discretion, not the finish line, FDA Law Blog (Hyman, Phelps & McNamara), 28 October 2026. www.thefdalawblog.com
- Sydney Lupkin, Trump administration will allow pharmacies to make popular peptides, NPR (via KUOW), 28 October 2026. www.kuow.org
- Brian Nowosielski, Dae Lee and Lucas Morgan, HHS lets pharmacies compound peptides as FDA writes official rule, Drug Topics, 29 October 2026. www.drugtopics.com
- 21 U.S.C. 353a, pharmacy compounding (section 503A of the FD&C Act), Cornell Legal Information Institute. www.law.cornell.edu
